MedTrace Logo

The Renal Safety in Patients With Chronic HCV Undergoing Sofosbuvir Containing Antiviral Therapy

NCT04169464 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-11-19

No results posted yet for this study

Summary

The aim of this study is to investigate the occurrence of AKI during antiviral therapy, when compared with baseline values in Egyptian patients.

In addition, the study aims to evaluate the change in insulin resistance value after treating patients from HCV.

Conditions

  • Egyptian Patients, HCV Treatment, Kidney Function

Interventions

DRUG

Sofosbuvir Oral Product

to investigate the drug effect on renal function and insulin resistance

Sponsors & Collaborators

  • MTI University

    lead OTHER

Principal Investigators

  • Dalia Zaafar, Phd · Lecturer of pharmacology and toxicology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-11-30
Completion
2019-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04169464 on ClinicalTrials.gov